LivaNova PLC
Index- P/E- EPS (ttm)-1.81 Insider Own0.39% Shs Outstand53.53M Perf Week-1.81%
Market Cap2.93B Forward P/E22.35 EPS next Y2.45 Insider Trans-1.05% Shs Float53.31M Perf Month-2.08%
Income-96.50M PEG- EPS next Q0.73 Inst Own- Short Float / Ratio4.07% / 5.12 Perf Quarter15.22%
Sales1.02B P/S2.88 EPS this Y62.50% Inst Trans1.45% Short Interest2.17M Perf Half Y-10.76%
Book/sh21.42 P/B2.56 EPS next Y7.78% ROA-4.20% Target Price72.17 Perf Year-24.76%
Cash/sh- P/C- EPS next 5Y-4.60% ROE-7.70% 52W Range41.82 - 88.00 Perf YTD-0.65%
Dividend- P/FCF49.04 EPS past 5Y-11.83% ROI-4.70% 52W High-37.30% Beta0.85
Dividend %- Quick Ratio2.50 Sales past 5Y1.40% Gross Margin70.90% 52W Low31.95% ATR1.77
Employees3000 Current Ratio3.00 Sales Q/Q-0.20% Oper. Margin-6.90% RSI (14)46.48 Volatility3.58% 3.05%
OptionableYes Debt/Eq0.47 EPS Q/Q-138.10% Profit Margin-9.50% Rel Volume0.47 Prev Close54.79
ShortableYes LT Debt/Eq0.45 EarningsFeb 22 BMO Payout- Avg Volume424.28K Price55.18
Recom1.70 SMA20-2.33% SMA50-0.36% SMA200-5.48% Volume109,925 Change0.71%
Dec-21-22Initiated Barclays Equal Weight $62
Apr-06-22Initiated Wolfe Research Outperform $95
Feb-24-22Upgrade UBS Neutral → Buy $96
Dec-03-21Initiated Goldman Buy $108
Aug-20-21Reiterated Needham Buy $104 → $117
Jul-20-21Upgrade Needham Hold → Buy $93
Mar-03-21Downgrade Berenberg Buy → Hold $84
Jan-05-21Downgrade Needham Buy → Hold
Sep-02-20Initiated Robert W. Baird Outperform $55
Jun-26-20Reiterated Needham Buy $84 → $76
Show Previous Ratings
Feb-03-23 11:20AM
Jan-27-23 12:55PM
Jan-18-23 09:00AM
Jan-10-23 09:15AM
Jan-07-23 09:16AM
08:58AM Loading…
Dec-15-22 08:58AM
Dec-13-22 04:05PM
Nov-30-22 09:00AM
Nov-24-22 05:34AM
Nov-17-22 09:00AM
Nov-08-22 09:00AM
Nov-07-22 12:28PM
Nov-02-22 07:25AM
Oct-26-22 10:02AM
06:26AM Loading…
Oct-21-22 06:26AM
Sep-21-22 09:00AM
Sep-15-22 09:00AM
Aug-03-22 07:15AM
Jul-31-22 08:42AM
Jul-28-22 09:44AM
Jul-25-22 02:24PM
Jul-08-22 07:33AM
Jun-22-22 09:00AM
Jun-15-22 06:34AM
Jun-14-22 08:30AM
May-25-22 08:30AM
May-23-22 06:51AM
May-05-22 06:09PM
07:25AM Loading…
May-04-22 07:25AM
Apr-08-22 09:00AM
Mar-24-22 09:00AM
Mar-14-22 09:00AM
Mar-02-22 06:00AM
Feb-24-22 05:29PM
Feb-23-22 07:15AM
Feb-17-22 03:07AM
Feb-07-22 11:36AM
Feb-01-22 12:10PM
Jan-26-22 06:35PM
Jan-19-22 06:49AM
Jan-12-22 09:00AM
Dec-22-21 09:41AM
Dec-14-21 07:44AM
Dec-09-21 07:38PM
Dec-02-21 09:00AM
Dec-01-21 09:00AM
Nov-23-21 09:00AM
Nov-21-21 01:19AM
Nov-17-21 05:25AM
Nov-12-21 05:47PM
Nov-10-21 09:00AM
Nov-08-21 09:00AM
Nov-03-21 03:10PM
Oct-27-21 03:03PM
Oct-11-21 11:08PM
Oct-05-21 06:23AM
Oct-04-21 09:00AM
Sep-30-21 11:10AM
Sep-14-21 07:05AM
Aug-26-21 09:00AM
Aug-16-21 07:30AM
Aug-03-21 07:47PM
Aug-02-21 04:51PM
Jul-28-21 06:30PM
Jul-21-21 03:02PM
Jul-12-21 03:21PM
Jul-02-21 04:02AM
Jun-28-21 09:00AM
Jun-15-21 09:00AM
Jun-02-21 07:05AM
Jun-01-21 05:30AM
May-13-21 09:00AM
May-03-21 05:02AM
Apr-28-21 05:00PM
Apr-26-21 09:00AM
Apr-20-21 09:00AM
Apr-19-21 09:00AM
Apr-14-21 11:45AM
Mar-25-21 09:00AM
Mar-17-21 07:05AM
Feb-24-21 12:00PM
Feb-01-21 02:17AM
Jan-20-21 09:00AM
Dec-07-20 08:00AM
Dec-04-20 09:00AM
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shvartsburg AlexCFODec 15Option Exercise0.0061306,873Dec 19 04:11 PM
McDonald DamienCEODec 15Sale54.562,220121,12383,749Dec 19 04:28 PM
Skeffington Keyna PidcockGeneral CounselSep 15Option Exercise0.0030008,231Sep 19 04:49 PM
Hebbelinck TruiChief Human Resources OfficerSep 15Option Exercise0.0044003,441Sep 19 04:44 PM
O'Kane SharonDirectorJun 15Option Exercise0.001,34607,607Jun 17 04:33 PM
Bianchi FrancescoDirectorJun 15Option Exercise0.001,34606,638Jun 17 04:31 PM
Saia Andrea LynnDirectorJun 15Option Exercise0.001,34608,121Jun 17 04:27 PM
Novak Alfred JDirectorJun 15Option Exercise0.001,346012,714Jun 17 04:25 PM
Moore Daniel JeffreyDirectorJun 15Option Exercise0.001,346025,976Jun 17 04:22 PM
Shvartsburg AlexCFOJun 15Option Exercise0.001,57707,002Jun 17 04:19 PM
ROSENTHAL ARTHUR LDirectorJun 15Option Exercise0.001,346023,729Jun 17 04:16 PM
SCHERMERHORN TODD CDirectorJun 15Option Exercise0.001,34602,370Jun 17 04:14 PM
KOZY WILLIAM ADirectorJun 15Option Exercise0.002,26408,584Jun 17 04:11 PM
Enxing Seng StacyDirectorJun 15Option Exercise0.001,34605,142Jun 17 04:08 PM
Moore Daniel JeffreyDirectorApr 01Sale83.421,00083,41624,630Apr 05 01:47 PM
McDonald DamienCEOMar 30Option Exercise0.0016,940088,376Mar 31 05:16 PM
Skeffington Keyna PidcockGeneral CounselMar 30Option Exercise0.002,86508,304Apr 01 10:12 AM
Shvartsburg AlexCFOMar 30Option Exercise0.001,95105,826Apr 01 10:11 AM
Dolci MarcoPresident CPMar 30Option Exercise0.002,80102,656Apr 01 10:09 AM
Hebbelinck TruiChief Human Resources OfficerMar 30Option Exercise0.002,24803,323Apr 01 10:07 AM
McDonald DamienCEOMar 29Sale81.502,784226,89676,993Mar 31 05:16 PM
McDonald DamienCEOMar 15Option Exercise0.003,182081,273Mar 17 10:35 AM
Skeffington Keyna PidcockGeneral CounselMar 15Option Exercise0.0045906,601Mar 17 10:32 AM
Shvartsburg AlexCFOMar 15Option Exercise0.0039004,576Mar 17 10:31 AM
Dolci MarcoSVP Global Operations, R&DMar 15Option Exercise0.005580934Mar 17 10:29 AM
Moore Daniel JeffreyDirectorMar 02Sale80.001,00080,00025,630Mar 03 07:48 PM
McDonald DamienCEOMar 01Option Exercise0.005,167080,520Mar 03 08:05 PM
Dolci MarcoSVP Global Operations, R&DMar 01Option Exercise0.006880688Mar 03 08:04 PM
Hebbelinck TruiChief Human Resources OfficerMar 01Option Exercise0.0055902,075Mar 03 08:02 PM
Skeffington Keyna PidcockGeneral CounselMar 01Option Exercise0.0077406,506Mar 03 07:52 PM
Moore Daniel JeffreyDirectorFeb 25Sale80.001,00080,00026,630Mar 01 04:58 PM